|
Press information 4 June 2008
“Follow-up research among patients consistently shows a marginal bone level reduction of just 0.4 mm or less for Astra Tech dental implants, a performance indicator at least three times superior to the industry norm. The findings involve hundreds of individual cases and are remarkable in their consistency,” says Lyndon Cooper, Professor of Dentistry in the Department of Prosthodontics at the University of North Carolina, who has performed one of the studies.
Professor Cooper is attending the second Astra Tech Dental World Congress in Washington, DC, held from June 4 to 7, where additional follow-up studies with long-term data are presented. Thousands of Astra Tech implants have been evaluated radiographically over a five-year period. Marginal bone levels were found to recede by less than 0.4 mm on average after one year, and was stable over the following years.
The current industry standard , based on research on other implant systems, shows a mean bone level reduction of about 1.5 mm after five years. Maintenance of the marginal bone level is a prerequisite for long-term esthetics and the successful function of the implant. “The limited marginal bone resorption being documented on Astra Tech implants indicates that it is time to reconsider our old ‘standard’ from 1986. The new standard should perhaps only allow 50% or less of the bone resorption currently accepted as a successful result,” says Tomas Albrektsson, Professor of Biomaterial Research at The Sahlgrenska Academy, University of Gothenburg, Sweden.
Dental implants from Astra Tech are among the most well documented on the market.
The Astra Tech Implant System™ was introduced in the late 1980s and now, almost twenty years later, the same implant system remains highly effective.
Thousands of delegates from 23 countries attend the Astra Tech World Congress at the Gaylord National Resort & Conference Center in Washington, DC, where more than 130 of the world’s most respected dental researchers present their latest findings in the field of implant dentistry.
For further information, please contact:
Björn Delin, Business Unit Director Dental, Astra Tech AB, Sweden, mob: +46 705 76 72 60
Janie Shen, Director Corporate Communications, Astra Tech Inc., USA Phone: +1 781 890 6800/6604
Visit Astra Tech www.astratechdental.com
About Astra Tech
Astra Tech AB, a subsidiary of the AstraZeneca group, develops, manufactures, markets dental implants and advanced disposable products for use within healthcare. The company develops products that enhance treatment results, simplify work for healthcare professionals and help cut healthcare costs.
In 2007, Astra Tech acquired the US company Atlantis Components, Inc. The acquisition gave Astra Tech access to the latest CAD/CAM technology for individually fabricated abutments based on each patient’s individual needs.
Astra Tech’s headquarters and production facilities are located in Mölndal, near Gothenburg, Sweden. The company operates globally through 16 subsidiaries and selected local partners. In North America, it is represented by Astra Tech Inc., 890 Winter Street, Waltham, MA 02451.
Albrektsson T and Zarb, G. A. Int J Prosthodont 1993;6(2):95-105.
|